Top-News
Professionelle Dienstleistungen Schweiz

Relief Therapeutics SA Aktie

Aktie
WKN:  A3EFB5 ISIN:  CH1251125998 US-Symbol:  RLFTF
5,9316 €
-0,8221 €
-12,18%
6,45 $ 31.10.24
Handeln Depot/Watchlist
Aktienanzahl *
11,01 Mio.
Marktkapitalisierung *
74,72 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.06.2024

Relief Therapeutics SA News

21.06.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) ...
17.06.22 - DGAP
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and ...
13.06.22 - DGAP
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for ...
08.06.22 - DGAP
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target ...
01.06.22 - DGAP
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA 01-Jun-2022 / ...
31.05.22 - DGAP
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National ...
26.05.22 - DGAP
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
Relief Therapeutics Holding SA / Key word(s): Study results Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. ...
23.05.22 - DGAP
Relief Therapeutics Expands U.S. Commercial Team
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Expands U.S. Commercial Team 23-May-2022 / 06:55 CET/CEST Release of an ad hoc announcement ...
11.05.22 - DGAP
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and ...
09.05.22 - DGAP
Relief Therapeutics to Participate in Industry and Investor Conferences in May
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in Industry and Investor Conferences in May 09.05.2022 / 07:00
06.05.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
Relief Therapeutics Holding SA / Key word(s): Study results Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians ...
06.05.22 - DGAP
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA 06-May-2022 / ...
27.04.22 - DGAP
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. ...
26.04.22 - DGAP
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints Drew Cronin-​Fine as Executive Director, Head of U.S. Marketing 26-Apr-2022 / 07:00 ...
22.04.22 - DGAP
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
Relief Therapeutics Holding SA / Key word(s): Regulatory Admission Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request ...
12.04.22 - DGAP
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
Relief Therapeutics Holding SA / Key word(s): Study results Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited ...
05.04.22 - DGAP
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process 05-...
01.04.22 - DGAP
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for ...
01.04.22 - DGAP
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Relief Therapeutics Holding SA / Key word(s): Study Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with ...
31.03.22 - DGAP
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Reports Full-Year 2021 Results and Provides Corporate Update 31-March-2022 / 07:00 CET/CEST Release of ...

Newssuche

Videos

newspaper
31.10.24 -13,28%
Technical Trading: 83% Trefferquote für diesen Trade
Nasdaq Long Typ: Turbo Open End WKN: VM433C Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »